UroGen Pharma Ownership | Who Owns UroGen Pharma?


OverviewForecastRevenueFinancialsChartTranscripts

UroGen Pharma Ownership Summary


UroGen Pharma is owned by 81.50% institutional investors, 9.18% insiders, and 9.32% retail investors. Rtw investments, lp is the largest institutional shareholder, holding 10.66% of URGN shares. UBS (Lux) Digital Health Equity SB USD is the top mutual fund, with 3.13% of its assets in UroGen Pharma shares.

URGN Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockUroGen Pharma81.50%9.18%9.32%
SectorHealthcare Stocks 47.06%8.01%44.93%
IndustryBiotech Stocks 44.97%7.82%47.21%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Rtw investments, lp3.56M10.66%$59.69M
Adage capital partners gp3.30M9.89%$55.37M
Great point partners2.91M8.71%$48.77M
Point72 asset management2.45M7.34%$41.10M
Menora mivtachim2.30M6.90%$38.64M
Blackrock2.19M6.57%$36.81M
Cowen and company2.10M6.29%$35.23M
Morgan stanley1.84M5.51%$30.85M
Cormorant asset management, lp1.65M4.94%$27.69M
Ubs asset management americas1.32M3.95%$22.15M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Great point partners2.91M9.34%$48.77M
Silverarc capital management1.10M4.36%$18.49M
Wildcat capital management495.61K2.04%$8.32M
Dafna capital management469.00K1.88%$7.87M
Cormorant asset management, lp1.65M1.60%$27.69M
Opaleye management412.00K1.58%$6.91M
Cowen and company2.10M0.97%$35.23M
Rtw investments, lp3.56M0.92%$59.69M
Parkman healthcare partners274.46K0.62%$4.61M
De lisle partners llp81.51K0.30%$1.37M

Top Buyers

HolderShares% AssetsChange
Adage capital partners gp3.30M0.10%2.00M
Cormorant asset management, lp1.65M1.60%1.65M
Morgan stanley1.84M0.00%1.45M
Point72 asset management2.45M0.11%1.34M
Ubs asset management americas1.32M0.01%1.32M

Top Sellers

HolderShares% AssetsChange
Ra capital management---3.08M
Superstring capital management lp---288.27K
Price t rowe associates inc /md/10.95K--256.19K
Harel insurance investments & financial services463.56K0.15%-209.92K
Laurion capital management lp---160.60K

New Positions

HolderShares% AssetsChangeValue
Cormorant asset management, lp1.65M1.60%1.65M$27.69M
Ubs asset management americas1.32M0.01%1.32M$22.15M
Dafna capital management469.00K1.88%469.00K$7.87M
Woodline partners lp303.74K0.05%303.74K$5.10M
Trexquant investment lp80.71K0.02%80.71K$1.35M

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-4.00
Toronto dominion bank-6.00
Systm wealth solutions-48.00
Eversource wealth advisors-57.00
Lindbrook capital-87.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 20241329.09%35,128,434-8.10%810.76%75-5.06%3050.00%
Jun 30, 20241202.56%38,225,51540.73%1142.03%7856.00%20-45.95%
Mar 31, 20241178.33%27,162,13526.89%751.71%50-24.24%3785.00%
Dec 31, 20231081.89%21,406,80020.71%661.16%666.45%20-9.09%
Sep 30, 202310619.10%17,734,02534.25%752.35%6234.78%2210.00%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
UBS (Lux) Digital Health Equity SB USD1.32M3.13%-
iShares Russell 2000 ETF957.94K2.27%-2.16K
Fidelity Small Cap Index351.12K0.83%-9.33K
MEDICAL BioHealth EUR Acc294.71K0.70%-238.32K
iShares Biotechnology ETF269.09K0.64%-1.61K
State St Russell Sm/Mid Cp® Indx NL Cl C262.40K0.62%-
iShares Russell 2000 Growth ETF258.82K0.61%-
Vanguard Russell 2000 ETF172.12K0.41%-1.09K
ARK Israel Innovative Technology ETF161.86K0.38%-
SPDR® Portfolio Developed Wld ex-US ETF120.41K0.29%-

Recent Insider Transactions


DateNameRoleActivityValue
Sep 09, 2024Schoenberg Mark Chief Medical OfficerSell$11.24K
Sep 09, 2024Smith Jason Drew General CounselSell$19.89K
Jun 10, 2024Schoenberg Mark Chief Medical OfficerSell$67.40K
Mar 18, 2024Schoenberg Mark Chief Medical OfficerSell$168.60K
Feb 01, 2024Smith Jason Drew General CounselSell$52.52K

Insider Transactions Trends


DateBuySell
2024 Q4--
2024 Q3-2
2024 Q2-1
2024 Q1-13
2023 Q3-1

URGN Ownership FAQ


Who Owns UroGen Pharma?

UroGen Pharma shareholders are primarily institutional investors at 81.50%, followed by 9.18% insiders and 9.32% retail investors. The average institutional ownership in UroGen Pharma's industry, Biotech Stocks , is 44.97%, which UroGen Pharma exceeds.

Who owns the most shares of UroGen Pharma?

UroGen Pharma’s largest shareholders are Rtw investments, lp (3.56M shares, 10.66%), Adage capital partners gp (3.3M shares, 9.89%), and Great point partners (2.91M shares, 8.71%). Together, they hold 29.25% of UroGen Pharma’s total shares outstanding.

Does Blackrock own UroGen Pharma?

Yes, BlackRock owns 6.57% of UroGen Pharma, totaling 2.19M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 36.81M$. In the last quarter, BlackRock increased its holdings by 477.14K shares, a 27.79% change.

Who is UroGen Pharma’s biggest shareholder by percentage of total assets invested?

Great point partners is UroGen Pharma’s biggest shareholder by percentage of total assets invested, with 9.34% of its assets in 2.91M UroGen Pharma shares, valued at 48.77M$.

Who is the top mutual fund holder of UroGen Pharma shares?

UBS (Lux) Digital Health Equity SB USD is the top mutual fund holder of UroGen Pharma shares, with 3.13% of its total shares outstanding invested in 1.32M UroGen Pharma shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools